T1002	drug 34 46	dipyridamole
T1004	drug 152 164	dipyridamole
T1006	component 254 262	caffeine
T1007	drug 315 324	adenosine
T1009	component 435 443	caffeine
T10013	mealTime 669 674	after
T10014	mode 675 683	infusion
T10015	component 687 695	caffeine
T10016	dosage 697 704	4 mg/kg
T10017	component 799 807	caffeine
T10018	food 860 866	coffee
T10019	drug 938 950	dipyridamole
T10024	drug 377 389	dipiridamole
T10025	population 415 426	one patient
T10020	pathology 767 775	ischemia
T10012	parameter 501 537	down-slope ST depressions on the ECG
T1003	parameter 34 74	dipyridamole-induced myocardial ischemia
T1005	parameter 377 411	dipiridamole-201Tl cardiac imaging
T10026	parameter 455 495	dipyridamole induced myocardial ischemia
T10011	parameter 579 590	scintigrams
T10027	parameter 711 714	ECG
T10029	parameter 734 745	scintigrams
T10028	parameter 938 972	dipyridamole-201Tl cardiac imaging
T10030	drugEffect 124 145	coronary vasodilation
T2001	component 17 25	Caffeine
T2008	component 350 358	caffeine
T20010	drug 455 467	dipyridamole
T20011	interaction 468 475	induced
T20023	interaction 289 311	competitive antagonist
T2003	interaction 26 33	reduces
T2007	pathology 543 571	reversible perfusion defects
T1	meal 435 454	caffeine abstinence
T2	meal 799 818	caffeine abstinence
#1	AnnotatorNotes T10027	exam clinique 
R2	target_protein_antagonism Arg1:T10018 Arg2:T10019	
#2	AnnotatorNotes R2	lié au mécanisme d'interaction supposé, décrit ligne 4 "competitive antagonist of adenosine"
R3	target_protein_antagonism Arg1:T1006 Arg2:T1007	
